BIOIO was founded based on two decades of research to understand better how drugs work. In particular, we leverage our learnings on how the widely used medicines, such as rapamycin, metformin, bisphosphonates, and antidepressants, work. This led us to define a gold standard for drug MoA elucidation, leading to our genetics-based MOAT platform. Increasingly, our process has become increasingly big data driven and automated. We propose this is key to accelerating drug development. Our team has evolved to add these in silico skills to virtualize our wet-lab.